What were the primary drivers of Abbott's sales growth in the reported period?

Abbott's sales growth was driven by a combination of factors, including the acquisitions of Guidant's vascular intervention and endovascular solutions businesses (completed in April 2006) and Kos Pharmaceuticals Inc. (completed in December 2006). Additionally, unit growth and the positive impact of a weaker U.S. dollar on international sales contributed to the overall increase. Key products like HUMIRA and Depakote also showed strong performance, particularly in the Pharmaceutical Products segment.

How did the company's profitability change compared to the previous year?

Abbott demonstrated improved profitability. Net earnings for the nine months ended September 30, 2007, increased by 9.6% to $2.4 billion. More significantly, operating earnings saw a substantial increase of 33.3% to $3.1 billion for the same period, indicating strong operational performance and effective cost management.

What is the company's liquidity and capital resources situation?

Abbott maintained a strong liquidity position. At September 30, 2007, the company had $1.9 billion in cash and cash equivalents. Current assets exceeded current liabilities by approximately $555 million. Furthermore, Abbott had substantial readily available financial resources, including unused lines of credit totaling $7.0 billion, supporting its commercial paper borrowing arrangements.

Are there any significant legal or contingent liabilities that investors should be aware of?

Abbott is involved in various legal proceedings and investigations. Notably, the company is facing pricing information litigation related to Medicare and Medicaid reimbursement, as well as patent disputes. While management believes the ultimate disposition of most of these matters will not materially adversely affect the company's financial position, cash flows, or results of operations, the resolution of certain pricing information cases could be material to quarterly cash flows or results of operations.

ABT 10-Q Quarterly Report Q3 FY2007 — Revenue, Net Income, EPS

Summary

Abbott Laboratories reported strong performance for the nine months ended September 30, 2007, with net sales increasing by 15% to $18.7 billion and net earnings rising by 9.6% to $2.4 billion. The company demonstrated robust operating earnings growth of 33.3% year-over-year for the nine-month period, reaching $3.1 billion. This growth was driven by significant increases across its key segments, particularly Pharmaceuticals and Vascular Products, bolstered by strategic acquisitions made in the prior year, including Guidant's vascular business and Kos Pharmaceuticals. The company also saw substantial improvement in its cash flow from operations, which increased to $4.1 billion for the first nine months, enabling continued investment in R&D and share repurchases. Financially, Abbott maintained a solid liquidity position with $1.9 billion in cash and cash equivalents and ample credit facilities. The company continued its commitment to shareholder returns through dividend payments and share repurchases, totaling approximately $1.0 billion in the first nine months of 2007. While facing some headwinds from generic competition in certain older products and increased R&D spending for pipeline development, the overall financial health and strategic execution position Abbott Laboratories for continued growth.

Key Highlights

1Net sales for the nine months ended September 30, 2007, increased by 15.0% to $18.7 billion compared to the prior year.
2Net earnings for the nine months ended September 30, 2007, grew by 9.6% to $2.4 billion, or $1.54 per diluted share.
3Operating earnings for the nine months ended September 30, 2007, increased significantly by 33.3% to $3.1 billion.
4Cash flow from operating activities for the first nine months of 2007 was strong at $4.1 billion.
5The company repurchased approximately $1.0 billion of its common shares during the first nine months of 2007 under its authorized repurchase program.
6The Vascular Products segment saw substantial sales growth of 80.0% for the nine months ended September 30, 2007, largely due to the acquisition of Guidant's vascular business.
7Abbott adopted new accounting standards (SFAS No. 157, SFAS No. 159, and FIN 48) effective January 1, 2007, with no material adverse impact on its financial position.

ABBOTT LABORATORIES Quarterly Report for Q3 Ended Sep 30, 2007

Summary

Key Highlights

Frequently Asked Questions